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RESUMO
Introdução: A papilomatose respiratória recorrente (PRR), que
é causado pelo papilomavírus humano tipos 6 e 11, é a neoplasia
benigna mais comum da laringe entre as crianças ea segunda
causa mais frequente de rouquidão na infância. É uma doen-
ça enigmática que pode ser devastadora para aqueles a quem
ela afeta. É muito mal compreendido, e investigação continua
na ativa assunto.
Objetivo: Esta revisão teve por objectivo proporcionar uma
visão global e uma atualização do que é conhecido sobre RRP
e que está à frente de interms therapies.This cirúrgica e
adjuvante foi realizada através de pesquisa das bases de dados
PubMed, MEDLINE, Index cumulativa de Enfermagem e Saú-
de Allied Literatura e Cochrane biblioteca electrónica procu-
rou usar os cabeçalhos de assunto ’’papilomatose respiratória
recorrente’’, ’’papilomatose laríngea juvenil’’, ''papilomatose
respiratória’’, ’’obstrução laríngea pediátrica’’ e ’’gestão das
vias aéreas''. Os resultados obtidos foram analisados de rele-
vância para o tema.
Discussão: O papilomavírus humano (HPV) é um pequeno
vírus de DNA que contêm. A papilomatose respiratória recor-
rente pode afetar pessoas de qualquer idade, com o paciente
mais jovem identificado em um dia de idade eo mais velho
de 84 anos. A apresentação mais comum é o sustentáculo da
PRR é hoarseness. The de terapia tem sido repetida debulking.
O objetivo é erradicar a doença, sem danificar as estruturas
normais. Nenhum única modalidade tem mostrado ser eficaz
na erradicação da PRR.
Conclusão: Papilomatose respiratória recorrente é uma do-
ença frustrante caprichoso com o potencial para consequên-
cias mórbidas por causa de seu envolvimento das vias aéreas
eo risco de degeneração maligna.
Palavras-chave: Herpesvirus Saimiriíneo 2.
SUMMARY
Introduction: The recurrent respiratory papillomatosis  (RRP),
which is caused by the human papilomavirus type 6 and 11,
is the most common benign neoplasm in the larynx among
infants and the second more frequent cause of the hoarseness
in childhood. Is a enigmatic disease that can be devastating
for those whom are affected. Is way misunderstood, and the
investigation is still on matter.
Objective: This review had as objective provide a global vision
and an update of what is recognized about the RRP and that
is ahead of interns therapies. This surgical and adjuvant was
performed through the research of database PubMed,
MEDLINE, Cumulative index to nursing and health, Allied
Literature and Cochrane. Eletronic library sought to use the
headers of the subject “Recurrent Respiratory Papillomatosis”,
“Juvenile Laryngeal Papillomatosis”, “Respiratory
Papillomatosis”, “Pediatric Laryngeal Obstruction” and “Airway
Management”. The obtained results were analyzed of relevance
for the theme.
Discussion: The human papillomavirus (HPV) is a little DNA
virus that contain. The recurrent respiratory papillomatosis can
affect people of any age, with the younger patient identified
in a day of age and the oldest with 84 years. The most common
presentation is the supporter of the RRP, it is the hoarseness.
The therapy has been repetitive and debulking. The objective
is to erradicate the disease, without damaging the normal
structures. None modality has proven effective in the eradication
of RRP.
Conclusion: Recurrent Respiratory Papillomatosis is a
frustrating disease, capricious with the potential of the morbid
consequences by the cause of involvement of the airway and
the risks of malignant degeneration.
Keywords: Herpesvirus Saimirineo 2.
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INTRODUCTION
The scientific knowledge of RRP has been a slowly
progressive one. It dated back to 1923 when Ullmann
verified its infectious etiology by injecting homogenized
papillomata from a child’s larynx into his own forearm and
observing the development of papillomata there (1).
Subsequently in 1956, a pediatrician made an association
between maternal condylomata and the risk of childhood
infection (2). In 1973 an intranuclear icosahedral virus was
identified in lesions by electron microscopy (3), and in
1980 human papillomavirus (HPV) DNA was identified in
papillomata (4). Although, initially called juvenile laryngeal
papillomatosis, the disease has been increasingly recognized
in adults and not only limited to the larynx. Therefore, it
generally goes by the name recurrent respiratory
Papillomatosis. It has been described to have a juvenile or
aggressive form and an adult or less aggressive form.
However, the aggressive form may occur in an adult and
vice versa. There has been an association between mater-
nal cervical HPV infection and the incidence of RRP (5).
Surgical debulking was advanced with the use of the CO
2
laser and suspension microlaryngoscopy in 1972 (6) which
remains a gold standard. Current lines of treatment include
the use of drugs to slow the disease progression. It should
be noted that frequent biopsies of patients and close
follow-up are needed to detect squamous metaplasia,
dysplasia,or conversion to SCC. Such a progression to SCC
may occur but is rare (7,8).
The objective of this review is to provide us with an
overview and an update of what is known about RRP in
terms of pathological science,epidemiology, clinical
presentation,diagnosis and treatment.It will also inform us
what lies ahead interms of surgical and adjuvant therapies.
METHOD
Databases for PubMed, MEDLINE, Cumulative Index
of Nursing and Allied Health Literature and Cochrane library
were electronically searched using the subject headings
Recurrent Respiratory Papillomatosis, laryngeal
papillomatosis, juvenile respiratory papillomatosis,pediatric
laryngeal obstruction and airway management.The results
generated were reviewed for relevance to the topic.
Pathological Science
Human papillomavirus (HPV) is a small, DNA-
containing, nonenveloped icosahedral (20-sided) capsid
virus with a double-stranded circular DNA that is 7900 base
pairs (bp) long.
Belongs to the Papovavirus family. “Papova” is an
acronym for the three types of viruses in the family -
papillomavirus, polyomavirus, and simian vacuolating virus.
There are only three papovaviruses pathogenic to humans:
HPV, and JC and BK viruses which are polyoma viruses (JC
virus has been implicated in progressive multifocal
leukencephalopathy and BK virus has been isolated from
urine of kidney transplant recipients).
90 subtypes of HPV are known (9), but only a
few subtypes commonly cause RRP. These are RRP 6
and 11. They also cause condyloma acuminata (genital
warts). To be a subtype, a strain has to exhibit less than
90% homology with other subtypes, and certain
subtypes which behave in a similar fashion clinically
have been found to have similar homology (10). These
include 6 and 11, 16 and 18, and 31, 33, and 35.
Today,with the use of viral probes, HPV DNA has been
identified in virtually every papilloma lesion studied.The
original strains identified were labeled 6C-6F but 6C
was later determined to be different enough to be
classified as its own strain, HPV 11.16 and 18 have been
implicated as causative in cancer, particularly of the
uterine cervix.
E6 and E7 are nuclear transforming proteins
sometimes made by the virus which have been implicated
in malignant transformation. They are thought to play a role
in molecular biological typing of individual lesions.
Epidemiology
Recurrent respiratory papillomatosis may affect
people of any age, with the youngest patient identified at
1 day of age and the oldest at 84 years (11). True incidence
and prevalence of RRP are uncertain. In a Danish
subpopulation incorporating 50% of the population of that
country, the incidence of laryngeal Papillomatosis was 3.84
cases per 100,000.The rate among children was 3.62 per
100,000, whereas adult-onset cases occurred at a rate of
3.94 per 100,000. These data are comparable with those
found in a recent U.S. survey, which estimated an incidence
in the pediatric population of 4.3 per 100,000 children and
1.8 per 100,000 adults.
This translates into approximately 2300 new pediatric
cases per year in the United States (12).
It has been estimated to affect 15,000 total people
in the United States, 6,000 of them being children. There
are 2300 new cases among children and 3600 new cases
among adults diagnosed each year, with an incidence of 4.3
and 1.8 per 100,000, respectively. Diagnosis and treatment
cost $151 million annually (13).
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Initially believed to be a disease of children it is now
known to have a bimodal distribution in ages with the first
peak in children, majority presenting by age five.
Approximately 25% will present by age one, 75% by age
five and the remainder of juvenile onset RRP by puberty
(14). Childhood-onset RRP (arbitrarily defined as patients
diagnosed at less than 12 y of age) is most often diagnosed
between 2 and 4 years of age.Adult RRP peaks between
the ages of 20 and 40 and has a slight male predilection;
distribution among boys and girls is approximately equal
and there are no apparent differences in surgical frequencies
by gender or ethnicity (14). Boys and girls are equally
affected. Retrospective and recent prospective studies
have confirmed that HPV may be passed by vertical
transmission from mother to child. In addition; Kashima et
al. (15) found that patients with childhood-onset RRP were
more likely to be firstborn and vaginally delivered than
were control patients of similar age. There is a predilection
for the firstborn child. In fact, the triad of the firstborn,
vaginally-delivered infant of a teenage mother has been
recognized as a risk factor for the disease. RRP is rare in non-
twin sibling pairs. In the past it was thought that children
with RRP would spontaneously remit at the onset of
puberty due to hormonal changes, but this has not been
found to be true.
Transmission is thought to be multi-factorial, but in
children the most common risk factor has been vertical
transmission during birth from maternal HPV infection.
Most studies indicate that juvenile-onset RRP occurs
during exposure from a mother with genital HPV infection
during normal vaginal delivery (16). Cesarean section
may provide protection from HPV, and only 1 of 109
patients born by Cesarean section developed RRP in one
study (17).
Because many babies are exposed during childbirth
and only a few develop RRP, it has been suggested that
genetically encoded host susceptibility may play a role in
disease progression (18).
Other postulated routes include hematogenous
spread and ascending transplacental inoculation. Mothers
of affected children can recall by history active or prior HPV
infection 50% of the time. However, the understanding of
the cause and effect is nebulous at best. It has been
estimated that 10-25% of women of childbearing age have
been shown to have evidence of latent or active HPV in
cervical swabs, and HPV DNA has been found in one-third
to one-half of aero-digestive tract swabs of children born to
affected mothers. However, the majority of these children
do not develop disease. The risk of developing disease is
not precisely known but has been estimated at 1 in 400
(10). There is not a consensus regarding the role of
cesarean section for prevention of disease in mothers with
HPV infection. Ultimately, the decision is one between a
woman and her obstetrician, but the literature generally
does not endorse prophylactic cesarean sections in the
absence of other indications (19). A landmark study by
Shah evaluated 109 children with RRP and found only one
to have been born by cesarean section, much lower than
would be predicted (20).
Clinical Presentation and Diagnosis
The most common presentation is of RRP is
hoarseness. Young children may also present with weak
cry, chronic cough, or stridor. Adults may present with
other symptoms such as globus. Persistent or progressive
stridor and dysphonia, with the possible development of
respiratory distress, are the most consistent signs and
symptoms of RRP in children. In the absence of severe
respiratory distress, a careful history should be obtained.
Information regarding the time of onset of symptoms,
possible airway trauma including a history of previous
intubation, and characteristics of the cry are, obviously,
important. Hoarseness, although a common and often
benign clinical complaint in young children, always indicates
some abnormality of structure or function. Because of the
precision of laryngeal mechanics, hoarseness may result
from a remarkably small lesion and thus be an early sign in
the course of a disease process. On the other hand, if the
lesion’s origin is remote from the vocal cords, hoarseness
may present as a late sign. The quality of the voice change
may give only limited clues to its etiology, while other
characteristics such as age of onset, rate of
progression,associated infection, history of trauma or surgery,
and the presence of respiratory or cardiac distress may be
of much greater significance. A low-pitched, coarse,
fluttering voice suggests a subglottic lesion, whereas a
highpitched, cracking voice; aphonia; or a breathy voice
suggests a glottic lesion. Associated high-pitched stridor
also suggests a glottic or subglottic lesion. Although stridor
that has been present since birth is more often associated
with laryngomalacia, subglottic stenosis, vocal cord paralysis,
or a vascular ring, it should be realized that neonates can
also present with papillomatosis. Associated symptoms
such as feeding difficulties, allergic symptoms, vocal abuse,
and the presence of hereditary congenital anomalies may
help distinguish RRP from alternative diagnoses, including
vocal fold nodules, vocal fold paralysis, subglottic cysts,
subglottic hemangioma, and subglottic stenosis.
In the absence of any history suggesting these
lesions, review of the peri-natal period may reveal a history
of maternal or paternal condylomata.
The diagnosis is usually made upon the visualization
of warty excrescences and confirmed by biopsy in the
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operating room. Histologically there is an epithelial
projection with a fibrovascular core, and there is associated
parakeratosis, koilocytosis, and acanthosis.
Although they can be found anywhere in the aero-
digestive tract, there appears to be a predilection for
areas where there is a junction of squamous and ciliary
epithelium. This includes the limen vestibuli (junction of
the nasal vestibule and the nasal cavity proper),
nasopharyngeal surface of the soft palate, midzone of the
laryngeal surface of the epiglottis, upper and lower
margins of the ventricle, undersurface of the vocal folds,
and the carina and bronchial spurs (9). Interestingly, virus
can be detected in the normal mucosa adjacent to lesions.
It is thought that this provides a reservoir for regeneration
of new papillomata (Figure 1).
The typical course is of recurrent lesions requiring
frequent debulking. However, every patient is different
and treatment must be tailored to the individual. Some
people require such frequent debulking that tracheotomy
is necessary for airway protection. This unfortunately
frequently leads to lesions around the tracheotomy site
(in essence, an iatrogenic squamociliary junction), but
traditional thinking has been that this predisposes to distal
tracheal disease. A recent study of children, however,
suggests that those who require tracheotomy have more
aggressive disease and have distal disease prior to
tracheotomy, and thus recommends that no child be
subjected to a tenuous airway merely to avoid tracheotomy
(21).
The natural history of the disease includes
spontaneous remission. It is impossible to know to whom
or when this will occur. The causes of remission are not
known, and while the exact incidence is not known, it is
thought that approximately one-third will remit by age
forty. This makes clinical trials somewhat difficult inasmuch
as it confounds the ability to tell who remitted due to
treatment and who remitted due to the natural history of
the illness.
Distal disease can develop and portends a poorer
prognosis due to its inaccessibility. Clinically patients
develop cavitary pulmonary lesions which can lead to
atelectasis, chronic infection, post-obstructive pneumonia,
and sepsis. It is thought distal disease is more common with
HPV 11.
Rarely the lesions can undergo malignant
degeneration which is almost uniformly fatal. One substantial
risk factor is prior history of irradiation, a form of therapy no
longer used to treat this disease.
TREATMENT
Surgical
The mainstay of therapy has been repeated
debulking. The goal is to eradicate disease without damaging
normal structures. No single modality has consistently been
shown to be effective in eradication of RRP.
The current standard of care is surgical therapy
with a goal of complete removal of papillomas and
preservation of normal structures. In patients in whom
anterior or posterior commissure disease or highly
aggressive papillomas are present, the goal may be
subtotal removal with clearing of the airway. It is advisable
to “debulk” as much disease as possible while preserving
normal morphological appearance and anatomy and
preventing the complications of subglottic and glottic
stenosis, web formation, and a diminished airway. The
CO
2
 laser has been favored over cold instruments in the
treatment of RRP involving the larynx, pharynx, upper
trachea, and nasal and oral cavities (12). A recent survey
of otolaryngologists showed that 92% favored the laser
(12). Although the CO
2
 laser is the most commonly used
laser for RRP in the larynx, the KTP, as well as the Argon
laser, could also be used. Papillomas that have extended
down the tracheo-bronchial tree often require use of the
KTP laser coupled to a ventilating bronchoscope for
removal. Occasionally, the ventilating resectoscope can
also be used in these circumstances. Care must be taken
with the laser to avoid disastrous complications such as
airway fire. Care must be taken to protect the operating
room personnel as papillomata have been demonstrated
in the laser plume. Good suction of smoke and laser
Figure 1. Pappillomatous lesion within the larynx.
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operating masks are usually sufficient. Eye protection
must be used to avoid laser damage to the globe. The
fractional concentration of oxygen in inspired gas (FIO2)
that is delivered to the patient should be as close to a
room-air mixture as possible. Ideally, the laser is not used
until the oxygen in the mixture is between 26% and 30%.
In selected circumstances, it may be warranted to proceed
with an FIO2 at or below 40%. These precautions are
taken to minimize the possibility of a laser-induced
endotracheal tube fire.As an initial procedure, a microcup
forceps is used for obtaining a biopsy specimen from the
bulkiest portion of papilloma.
Microdebrider is a relatively new device used in the
removal of papillomas is the powered by laryngeal shaver
blade (Xomed Surgical Microdebrider). Advocates of this
technique claim that the shaver is safer,more accurate,
prevents thermal injury, and the post-procedure oedema
that may be associated with the use of the laser is
minimized as tissue injury resulting from the shaver
technique is confined to the superficial mucosa only. FLINT
(22) stated that his patients who have been previously
treated with the laser have reported reduced postoperative
pain and quicker recovery of voice since he adopted the
shaver technique. Using the shaver blade with the aid of a
rigid telescope with a video system and a Hollinger-style
laryngoscope, lesions can be easily removed in the subglottic
region and trachea. For treatment of the difficult-to-manage
airway, the shaver isinvaluable as it may be used to debulk
tissue in proximity or direct contact with the endotracheal
tube. PATEL and MACKENZIE (23) assessed the value of the
new device in five adult patients with recurrent respiratory
papillomatosis who had previously undergone laser surgery.
They reported that shaver excision of papillomas provided
good clearance of disease,easy collection of pathological
samples, and a potentially safer and faster alternative to
laser excision.
Management of the airway is controversial. In the
apnea technique the patient is intubated and administered
100% oxygen for a period of time. The tube is then
removed for a period of time while the surgeon works. The
patient is then reintubated and reoxygenated. This may be
advantageous in pediatric airways in which there is not
much room to work around a tube. Other methods include
use of a laser-safe tube and spontaneous ventilation.
Another common method is jet ventilation. Although this
is generally felt to be safe, there is concern that this method
may lead to distal inoculation of the virus. In patients with
an existing tracheotomy, a metal tracheotomy tube can be
placed to allow laser surgery to be carried out safely. A
recent survey of otolaryngologists found the percent who
favored the various techniques as follows: laser-safe tube
46%, jet ventilation 25%, apneic 16%, and spontaneous
12% (12).
ADJUVANT
Although surgical management remains the mainstay
therapy for RRP, ultimately, as many a 10% of patients with
the disease require some form of adjuvant therapy. The
most widely adopted criteria for initiating adjuvant therapy
are a surgery requirement of more than four procedures
per year, distal multisite spread of disease, and/or rapid
regrowth of papilloma disease with airway compromise.
Newer therapies which have been tested include
alfa-interferon, indole-3-carbinol, acyclovir, retinoic acid,
ribavirin, methotrexate, cidofovir, and photodynamic
therapy. The most commonly recommended adjuvant
therapy is interferon (12).
Interferon has been used in treating recurrent
respiratory papillomatosis in the United States since the
early 1980s. The mechanism of action of interferon is
complex. It has an antiproliferative action slowing target
cell growth by depleting essential metabolites,thus
increasing the length of the multiplication cycle.
It is a product of human leukocytes, which has been
shown to reduce the growth rate at which the papillomata
grow, although Healy demonstrated that the initial benefit
seen at six months was gone by one year (24). Although
interferon has no direct anti-viral action, it does reduce the
translation of viral proteins by interfering with normal host
cell translation mechanisms and induce synthesis of
intracellular enzymes that act to control viral growth (6).
Interferon decreases the growth of papillomas and increases
the time interval between surgical procedures. Interferon
induces complete resolution of clinical disease in
approximately 30% to 50% of patients and partial resolution
in 20% to 42% (25,26,27).
Current standard of care includes therapy for patients
requiring surgery greater than four times per year (12). The
dose is increased to a target of 3 MU/m2 body surface areas.
It is continued for at least six months. Its side effects include
flu-like symptoms, elevation of hepatic enzymes, renal
insufficiency, anorexia, seizures, GI distress, and transient
numbness (10). There is some suggestion that neutralizing
antibodies may blunt its beneficial effect and that this may
vary by brand (28).
Indole-3-carbinol is a naturally-occurring product of
cruciferous vegetables which affects estrogen metabolism,
shifting production to anti-proliferative estrogens. Only
25% of mice who were injected with papillomata and then
fed with it developed disease as compared to 100% of
controls (29). As compared with interferon some patients
have a much more pronounced response than do others.
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A recent phase I trial showed a third of patients undergoing
remission, a third slowing their rate of growth, and a third
with no response (30). Adult’s dosage is 200-400 mg while
100-200 mg for children weighing less than 25 kg (10). It
is well-tolerated.
Acylovir is a nucleoside analog that inhibits thymidine
kinase, which is present in Herpesviruses but not HPV. A
recent study has shown that some adults with RRP have
molecular evidence of co-infection with other viruses,
particularly HSV. It is felt that acyclovir acts to decrease
disease by treating HSV which may potentiate HPV.
However, HSV was not found in papillomata of children in
one study (31, 32).
Retinoic acid is a Vitamin A derivative which has
been shown to modulate epithelial differentiation. It is
used clinically in a variety of different settings, but its use
in RRP is still limited. Side effects include dry skin and
chelitis.
Photodynamic therapy involves the administration
of a photosensitizing agent, dihematoporphyrin, which is
concentrated in rapidly growing tissues. Following
administration of this agent, the lesions are then excised
with a tunable argon pump dye laser which preferentially
destroys the tissues which concentrated the dye. The main
side effect is photosensitivity which lasts weeks to months,
and has sometimes led to hospitalizations for cutaneous
burns.
Ribavirin is also a nucleoside analog which has been
shown to be useful in respiratory syncitial virus.
Methotrexate inhibits DNA synthesis and repair by
affecting folate metabolism. It has been used with some
success in some patients.
Cidofovir inhibits DNA polymerase and has been
used successfully in AIDS-related infections. Investigation
is currently underway and has been complicated by the
fact that this drug may be carcinogenic.
CONCLUSION
Recurrent respiratory Papillomatosis is a frustrating,
capricious disease with the potential for morbid
consequences because of its involvement of the airway
and the risk of malignant degeneration. Recurrent respiratory
papillomatosis is a disease, which, although relatively
uncommon, causes a substantial human and financial cost.
Although the aetiological role of human papilloma virus has
been well established, much remains to be understood
regarding the precise mechanism of viral transmission, and
the risk of disease expression in infants delivered to
mothers with cervical human papilloma virus infection.
The natural history of this disease is diverse. Although some
patients enjoy an early spontaneous remission, some suffer
from frequent and inexorable recurrences over many
decades,occasionally suffering the catastrophic complication
of malignant transformation. Unfortunately, there are as yet
no clear prognostic indicators and this is certainly one area
needing further investigation.Howerever,this article threw
more lights in the current areas of surgical and adjuvant
therapies.
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